Table IV.
Comparison of patients who did receive HDT/SCT to those who did not
| Variable | No HDT/SCT N=18 N (%) |
Received HDT/SCT N=15 N (%) |
p-value |
|---|---|---|---|
| Median age, years (range) | 68 (34–83) | 59 (27–69) | 0.03 |
| Age at diagnosis | 0.06 | ||
| ≤60 years | 5 (28) | 9 (60) | |
| >60 years | 13 (72) | 6 (40) | |
| Sex | 0.48 | ||
| Female | 4 (22) | 5 (33) | |
| Male | 14 (78) | 10 (67) | |
| Karnofsky performance score | 0.79 | ||
| 70 | 3 (17) | 2 (13) | |
| 80–100 | 15 (83) | 13 (87) | |
| Diagnosis | 0.64 | ||
| PTCL-NOS | 10 (56) | 11 (73) | |
| AITL, | 5 (28) | 3 (20) | |
| ALCL, T- and null cell types | 3 (17) | 1 (7) | |
| Ann Arbor Stage | 0.84 | ||
| II | 2 (11) | 2 (13) | |
| III – IV | 16 (89) | 13 (87) | |
| B symptoms | 0.57 | ||
| No | 9 (50) | 9 (60) | |
| Yes | 9 (50) | 6 (40) | |
| IPI Score | 0.65 | ||
| Low | 4 (22) | 5 (33) | |
| Low – intermediate | 4 (22) | 5 (33) | |
| High – intermediate | 6 (33) | 3 (20) | |
| High | 4 (22) | 2 (13) | |
| Lactate dehydrogenase | 0.85 | ||
| Normal | 9 (50) | 8 (53) | |
| Elevated | 9 (50) | 7 (47) | |
| Extranodal involvement | 0.39 | ||
| 0–1 | 12 (67) | 12 (80) | |
| 2 or more | 6 (33) | 3 (20) | |
| Median number of chemotherapy cycles (range) | 2 (1–6) | 4 (1–6) | 0.03 |
HDT/SCT, high dose therapy and stem cell transplantation, PTCL, peripheral T-cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; IPI, International Prognostic Index.